Get the Stockscreener App
8.7987
0.73%
-0.0713
Adma Biologics Inc stock is traded at $8.7987, with a volume of 388.02K.
It is down -0.73% in the last 24 hours and up +3.59% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
See More
Previous Close:
$8.87
Open:
$8.71
24h Volume:
388.02K
Relative Volume:
0.08
Market Cap:
$2.04B
Revenue:
$509.86M
Net Income/Loss:
$165.35M
P/E Ratio:
12.98
EPS:
0.6779
Net Cash Flow:
$107.55M
1W Performance:
-3.88%
1M Performance:
+3.59%
6M Performance:
-49.69%
1Y Performance:
-51.03%
1-Day Range:
$8.64
$8.825
1-Week Range:
$8.64
$9.33
52-Week Range:
$7.2101
$20.46
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
8.795 | 2.08B | 509.86M | 165.35M | 107.55M | 0.6779 |
VRTX
Vertex Pharmaceuticals Inc
|
475.00 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.97 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.27 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.08 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.88 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Caledonian Record
ADMA Biologics, Inc. Notice of August 10, 2026 Application - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines – ADMA - FinancialContent
Important Notice to Long-Term Shareholders of ADMA - GlobeNewswire
ADMA Shareholder Alert: ADMA Biologics, Inc. Securities Class Action LawsuitInvestors With Losses May Contact The Gross Law Firm - PR Newswire
INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with - GlobeNewswire
ADMA Court News: ADMA Biologics Class Action Lawsuit Alleges Securities Fraud on behalf of Investors with Losses - PR Newswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA - GlobeNewswire Inc.
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance Singapore
Can ADMA Biologics (NASDAQ:ADMA) Extend Its Small-Cap Rally? - Kalkine Media
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, - GlobeNewswire
Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of - GlobeNewswire
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? - Yahoo Finance
2026-07-13 | ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ADMA | Press Release - Stockhouse
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - Key Biscayne Portal
ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds - Stocktwits
What Are the Allegations Against ADMA Biologics - Kavout | AI
How (ADMA) Movements Inform Risk Allocation Models - Stock Traders Daily
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - FinancialContent
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - PR Newswire
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders - GlobeNewswire
ADMA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - AOL.com
ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence - Stocktwits
ADMA UPCOMING DEADLINE: The Gross Law Firm Alerts ADMA - GlobeNewswire
2026-07-10 | ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ADMA | Press Release - Stockhouse
ADMA Biologics (NASDAQ:ADMA) Channel Stuffing Claims - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming DeadlinesADMA - PR Newswire
INVESTOR DEADLINE ALERT: ADMA Biologics, Inc. (ADMA) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NewMediaWire
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ADMA Investor Alert: ADMA Biologics, Inc. Investors with Large Losses Should Contact Robbins ... - Caledonian Record
ADMA Investor Alert: ADMA Biologics, Inc. Investors with - GlobeNewswire
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - TradingView
ADMA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - marketscreener.com
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
ADMA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ADMA BIOLOGICS, INC. Securities LawsuitContact Levi & Korsinsky - Business Wire
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER ALERT Bernstein - GlobeNewswire
INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery? - TradingView
DEADLINE ALERT for VIA, Z, ADMA, and ERAS: The Law Offices - GlobeNewswire
Lost Money on ADMA BIOLOGICS, INC. (ADMA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REMINDER: ADMA Biologics, Inc. Investors With Significant Losses Must Act By August 10, 2026 – Kirby McInerney LLP - GlobeNewswire
ADMA Investment Loss: ADMA Biologics Investors that Lost - GlobeNewswire
ADMA Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - marketscreener.com
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel ... - Caledonian Record
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, - GlobeNewswire
ADMA Biologics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsADMA - AOL.com
ADMA BIOLOGICS CLASS ACTION REMINDER: Bragar Eagel & - GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
2026-07-07 | ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ADMA | Press Release - Stockhouse
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Jerrold B | Director |
May 12 '26 |
Buy |
8.01 |
12,500 |
100,125 |
513,884 |
| Grossman Jerrold B | Director |
May 11 '26 |
Buy |
8.01 |
12,500 |
100,125 |
501,384 |
| Guiheen Lawrence P. | Director |
Mar 13 '26 |
Option Exercise |
3.66 |
30,000 |
109,800 |
135,520 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
1.48%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):